A wide application Patient Monitor for adults, paediatrics, neonates and animals
October 17, 2018
Source: drugdu
1,953
Patient monitors are medical equipment that helps read multiple biological parameters of patients simultaneously. They are the most useful in ICUs of hospitals, ambulances, and emergency departments.
Ddu (Drugdu.com), the leading global pharmaceutical and medical devices platform, eases the difficulty of customers in finding the best patient monitors. The reputed Promise Technology Co., Ltd. presents its 12.1-inch multi-parameter patient monitor for adult, pediatric, neonatal, and veterinary use.
This patient monitor has a patented in-house design and an elegant appearance. It is equipped with a steady 12.1-inch monitor which is suitable for bedside and transferring the patient. It has a unique one-key-switching for a total of 7 display interfaces. It comes in a waterproof case in strictly abiding with IPX1 on CE regulations. Hence, it has a wide application for adult, pediatric and neonatal and veterinary use. It is CE certified and comes with a warranty of 1 year.
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cornerstone Pharmaceuticals has reached a strategic cooperation on anti-PD-L1 monoclonal antibodies in the Middle East and Africa regions November 22, 2024
- Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan November 22, 2024
- Junshi Biotechnology introduces two cancer dual target fusion protein drugs November 22, 2024
- China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical November 22, 2024
- As the industry is going down, more and more pharmaceutical companies are seeking to “exit”? November 22, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
